Drug Trial Radar · NCT07489612
QLS1410 in Participants With Uncontrolled Hypertension
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
260
Planned (sponsor's estimate)
Start
Apr 2026
Primary completion
Dec 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to measure the efficacy and safety of QLS1410 in participants with uncontrolled hypertension (uHTN) or treatment-resistant hypertension (rHTN). The main objective is to compare the difference in systolic blood pressure(SBP) change from baseline at Week 12 of treatment between participants receiving QLS1410 tablets and participants receiving placebo tablets.
Conditions
- Hypertension (HTN)
Interventions
Dose 1 of QLS1410Drug
QLS1410 tablet administered orally, once daily (QD).
Dose 2 of QLS1410Drug
QLS1410 tablet administered orally, once daily (QD).
Dose 3 of QLS1410Drug
QLS1410 tablet administered orally, once daily (QD).
placeboDrug
Matching placebo tablet administered orally, once daily (QD).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in mean seated systolic blood pressure (SBP) at week 12Time frame: At week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Qilu Hospital of Shandong University
Jinan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.